Clostridium difficile infection an overview of the disease and its pathogenesis, epidemiology and interventions

Gut Microbes

Volumn 1, Issue 4, 2010, Pages 234-242

  Viswanathan, V K ^a   Mallozzi, M J ^a   Vedantam, Gayatri ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

CDAD; CDI; Clostridium difficile; Hypervirulent; Infection; Infection control; Pathogenesis; Spore

Indexed keywords

EID: 80051679965     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.4161/gmic.1.4.12706     Document Type: Article

References (146)

1. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals 1996-2003. Emerg Infect Dis 2006; 12:23-5.
2. McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe 2009; 15:274-80.
3. Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 2009; 30:57-66.
4. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007; 28:1219-27.
5. O'Connor JR, Johnson S, Gerding DN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 2009; 136:1913-24.
6. Pituch H. Clostridium difficile is no longer just a nosocomial infection or an infection of adults. Int J Antimicrob Agents 2009; 33:42-5.
7. Janka J, O'Grady N P. Clostridium difficile infection: current perspectives. Curr Opin Crit Care 2009; 15:149-53.
8. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7:526-36.
9. Urban E, Terhes G, Markotics A, Soki J, Nagy E. Rare extraintestinal infection caused by toxin-producing Clostridium difficile. Anaerobe 2010; 16:301-3.
10. Lavallee C, Laufer B, Pepin J, Mitchell A, Dube S, Labbe AC. Fatal Clostridium difficile enteritis caused by the BI/NAP1/027 strain: a case series of ileal C. difficile infections. Clin Microbiol Infect 2009; 15:1093-9.
11. Croagh DG, Bach S P, Keck J. A rare cause of acute abdomen after proctocolectomy. Am J Surg 2009; 197:41-2.
12. Boice JL. Reactive arthritis induced by Clostridium difficile. West J Med 1994; 160:171-2.
13. Libby DB, Bearman G. Bacteremia due to Clostridium difficile-review of the literature. Int J Infect Dis 2009; 13:305-9.
14. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009; 15:1554-80.
15. Pant C, Madonia P, Minocha A. Does PPI therapy predispose to Clostridium difficile infection? Nat Rev Gastroenterol Hepatol 2009; 6:555-7.
16. Vaishnavi C. Established and potential risk factors for Clostridium difficile infection. Indian J Med Microbiol 2009; 27:289-300.
17. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments and outcomes. J Infect 2009; 58:403-10.
18. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9.
19. Crogan NL, Evans BC. Clostridium difficile: an emerging epidemic in nursing homes. Geriatr Nurs 2007; 28:161-4.
20. Buchner AM, Sonnenberg A. Epidemiology of Clostridium difficile infection in a large population of hospitalized US military veterans. Dig Dis Sci 2002; 47:201-7.
21. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42:758-64.
22. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769-75.
23. Johnson S. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int J Antimicrob Agents 2009; 33:33-6.
24. Johnson S, Adelmann A, Clabots CR, Peterson LR, Gerding DN. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis 1989; 159:340-3.
25. Wilcox MH, Spencer RC. Clostridium difficile infection: responses, relapses and re-infections. J Hosp Infect 1992; 22:85-92.
26. Dumford DM, 3rd, Nerandzic MM, Eckstein BC, Donskey CJ. What is on that keyboard? Detecting hidden environmental reservoirs of Clostridium difficile during an outbreak associated with North American pulsed-field gel electrophoresis type 1 strains. Am J Infect Control 2009; 37:15-9.
27. Gerding DN, Muto CA, Owens RC Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008; 46:43-9.
28. Dubberke ER, Reske KA, Noble-Wang J, Thompson A, Killgore G, Mayfield J, et al. Prevalence of Clostridium difficile environmental contamination and strain variability in multiple health care facilities. Am J Infect Control 2007; 35:315-8.
29. Grainger M. A staff nurse's perspective of infection control problems. Br J Nurs 2005; 14:912-6.
30. Rupnik M. Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. FEMS Microbiol Rev 2008; 32:541-55.
31. Song K P, Ow SE, Chang SY, Bai XL. Sequence analysis of a new open reading frame located in the pathogenic-ity locus of Clostridium difficile strain 8,864. FEMS Microbiol Lett 1999; 180:241-8.
32. Pothoulakis C. Effects of Clostridium difficile toxins on epithelial cell barrier. Ann NY Acad Sci 2000; 915:347-56.
33. Gerhard R, Nottrott S, Schoentaube J, Tatge H, Olling A, Just I. Glucosylation of Rho GTPases by Clostridium difficile toxin A triggers apoptosis in intestinal epithelial cells. J Med Microbiol 2008; 57:765-70.
34. Dupuy B, Govind R, Antunes A, Matamouros S. Clostridium difficile toxin synthesis is negatively regulated by TcdC. J Med Microbiol 2008; 57:685-9.
35. Matamouros S, England P, Dupuy B. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol 2007; 64:1274-88.
36. Mani N, Dupuy B. Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc Natl Acad Sci USA 2001; 98:5844-9.
37. Dupuy B, Sonenshein AL. Regulated transcription of Clostridium difficile toxin genes. Mol Microbiol 1998; 27:107-20.
38. Purdy D, O'Keeffe TA, Elmore M, Herbert M, McLeod A, Bokori-Brown M, et al. Conjugative transfer of clostridial shuttle vectors from Escherichia coli to Clostridium difficile through circumvention of the restriction barrier. Mol Microbiol 2002; 46:439-52.
39. Heap JT, Kuehne SA, Ehsaan M, Cartman ST, Cooksley CM, Scott JC, et al. The ClosTron: Mutagenesis in Clostridium refined and streamlined. J Microbiol Methods 2009.
40. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458:1176-9.
41. Cartman ST, Minton NP A mariner-based transposon system for in vivo random mutagenesis of Clostridium difficile. Appl Environ Microbiol 2010; 76:1103-9.
42. Barth H, Aktories K, Popoff MR, Stiles BG. Binary bacterial toxins: biochemistry, biology and applications of common Clostridium and Bacillus proteins. Microbiol Mol Biol Rev 2004; 68:373-402.
43. Eidhin DN, Ryan AW, Doyle RM, Walsh JB, Kelleher D. Sequence and phylogenetic analysis of the gene for surface layer protein, slpA, from 14 PCR ribotypes of Clostridium difficile. J Med Microbiol 2006; 55:69-83.
44. Merrigan MM, Gerding DN, Vedantam G. Hypervirulent Clostridium difficile strains have altered protein expression and host-cell adherence. Eighth Biennial Conference of the Anaerobe Society of America PI-12 (Boise, Idaho) 2006.
45. Drudy D, Calabi E, Kyne L, Sougioultzis S, Kelly E, Fairweather N, et al. Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol Med Microbiol 2004; 41:237-42.
46. Kuijper EJ, van den Berg RJ, Brazier JS. Comparison of molecular typing methods applied to Clostridium difficile. Methods Mol Biol 2009; 551:159-71.
47. Stubbs SL, Brazier JS, O'Neill GL, Duerden BI. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999; 37:461-3.
48. Brazier JS. Typing of Clostridium difficile. Clin Microbiol Infect 2001; 7:428-31.
49. Clabots CR, Johnson S, Bettin KM, Mathie PA, Mulligan ME, Schaberg DR, et al. Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems. J Clin Microbiol 1993; 31:1870-5.
50. Killgore G, Thompson A, Johnson S, Brazier J, Kuijper E, Pepin J, et al. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism and surface layer protein A gene sequence typing. J Clin Microbiol 2008; 46:431-7.
51. Marsh JW, O'Leary MM, Shutt KA, Sambol SP, Johnson S, Gerding DN, et al. Multilocus variable number tandem repeat analysis and multilocus sequence typing reveal genetic relationships among Clostridium difficile isolates genotyped by restriction endonuclease analysis. J Clin Microbiol 2010; 48:412-8.
52. Karjalainen T, Saumier N, Barc MC, Delmee M, Collignon A. Clostridium difficile genotyping based on slpA variable region in S-layer gene sequence: an alternative to serotyping. J Clin Microbiol 2002; 40:2452-8.
53. Sell TL, Schaberg DR, Fekety FR. Bacteriophage and bacteriocin typing scheme for Clostridium difficile. J Clin Microbiol 1983; 17:1148-52.
54. Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Cmaj 2004; 171:466-72.
55. Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254-60.
56. Eggertson L. C. difficile may have killed 2000 in Quebec: study. Cmaj 2005; 173:1020-1.
57. Barbut F, Gariazzo B, Bonne L, Lalande V, Burghoffer B, Luiuz R, et al. Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study 2000-2004. Infect Control Hosp Epidemiol 2007; 28:131-9.
58. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova S V, Sambol S P, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-41.
59. Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26:273-80.
60. Katikireddi V. UK launches inquiry into Clostridium difficile outbreak. Cmaj 2005; 173:138.
61. Gerding DN. Clindamycin, cephalosporins, fluoroqui-nolones and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis 2004; 38:646-8.
62. van den Berg RJ, Schaap I, Templeton KE, Klaassen CH, Kuijper EJ. Typing and subtyping of Clostridium difficile isolates by using multiple-locus variable-number tandem-repeat analysis. J Clin Microbiol 2007; 45:1024-8.
63. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366:1079-84.
64. th General Meeting of the American Society for Microbiology, Philadelphia, PA Poster B-251 2009.
65. th General Meeting of the American Society for Microbiology, Boston, MA Poster B-156 2008.
66. Akerlund T, Svenungsson B, Lagergren A, Burman LG. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol 2006; 44:353-8.
67. Freeman J, Baines SD, Saxton K, Wilcox MH. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 2007; 60:83-91.
68. Karlsson S, Burman LG, Akerlund T. Induction of toxins in Clostridium difficile is associated with dramatic changes of its metabolism. Microbiology 2008; 154:3430-6.
69. Dineen SS, Villapakkam AC, Nordman JT, Sonenshein AL. Repression of Clostridium difficile toxin gene expression by CodY. Mol Microbiol 2007; 66:206-19.
70. Dupuy B, Raffestin S, Matamouros S, Mani N, Popoff MR, Sonenshein AL. Regulation of toxin and bacterio-cin gene expression in Clostridium by interchangeable RNA polymerase sigma factors. Mol Microbiol 2006; 60:1044-57.
71. Karlsson S, Lindberg A, Norin E, Burman LG, Akerlund T. Toxins, butyric acid and other short-chain fatty acids are coordinately expressed and downregu-lated by cysteine in Clostridium difficile. Infect Immun 2000; 68:5881-8.
72. Dupuy B, Matamouros S. Regulation of toxin and bacteriocin synthesis in Clostridium species by a new subgroup of RNA polymerase sigma-factors. Res Microbiol 2006; 157:201-5.
73. Akerlund T, Persson I, Unemo M, Noren T, Svenungsson B, Wullt M, et al. Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1. J Clin Microbiol 2008; 46:1530-3.
74. Huang H, Weintraub A, Fang H, Nord CE. Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents 2009; 34:516-22.
75. Pelaez T, Alcala L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002; 46:1647-50.
76. Dworczynski A, Sokol B, Meisel-Mikolajczyk F. Antibiotic resistance of Clostridium difficile isolates. Cytobios 1991; 65:149-53.
77. Baines SD, O'Connor R, Freeman J, Fawley WN, Harmanus C, Mastrantonio P, et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62:1046-52.
78. Vedantam G. Antimicrobial resistance in Bacteroides spp.: occurrence and dissemination. Future Microbiol 2009; 4:413-23.
79. Mutlu E, Wroe AJ, Sanchez-Hurtado K, Brazier JS, Poxton IR. Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland. J Med Microbiol 2007; 56:921-9.
80. Razavi B, Apisarnthanarak A, Mundy LM. Clostridium difficile: emergence of hypervirulence and fluoroqui-nolone resistance. Infection 2007; 35:300-7.
81. Huang H, Weintraub A, Fang H, Nord CE. Community acquired Clostridium difficile infection due to a moxi-floxacin susceptible ribotype 027 strain. Scand J Infect Dis 2009; 41:158-9.
82. Surveillance for community-associated Clostridium difficile-Connecticut 2006. MMWR Morb Mortal Wkly Rep 2008; 57:340-3.
83. Severe Clostridium difficile-associated disease in populations previously at low risk-four states 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1201-5.
84. Limbago BM, Long CM, Thompson AD, Killgore GE, Hannett GE, Havill NL, et al. Clostridium difficile strains from community-associated infections. J Clin Microbiol 2009; 47:3004-7.
85. Stark PL, Lee A, Parsonage BD. Colonization of the large bowel by Clostridium difficile in healthy infants: quantitative study. Infect Immun 1982; 35:895-9.
86. Stark PL, Lee A. Clostridia isolated from the feces of infants during the first year of life. J Pediatr 1982; 100:362-5.
87. Wilcox MH, Planche T. Clostridium difficile infection. BMJ 2009; 338:2528.
88. Riggs MM, Sethi AK, Zabarsky T F, Eckstein EC, Jump RL, Donskey CJ. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007; 45:992-8.
89. Matsuki S, Ozaki E, Shozu M, Inoue M, Shimizu S, Yamaguchi N, et al. Colonization by Clostridium difficile of neonates in a hospital and infants and children in three day-care facilities of Kanazawa, Japan. Int Microbiol 2005; 8:43-8.
90. Emeruwa AC, Oguike JU. Incidence of cytotoxin producing isolates of Clostridium difficile in faeces of neonates and children in Nigeria. Microbiologica 1990; 13:323-8.
91. Cohen MB. Clostridium difficile infections: emerging epidemiology and new treatments. J Pediatr Gastroenterol Nutr 2009; 48:63-5.
92. Kim J, Smathers SA, Prasad P, Leckerman KH, Coffin S, Zaoutis T. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States 2001-2006. Pediatrics 2008; 122:1266-70.
93. Garey KW, Jiang ZD, Yadav Y, Mullins B, Wong K, Dupont HL. Peripartum Clostridium difficile infection: case series and review of the literature. Am J Obstet Gynecol 2008; 199:332-7.
94. Zilberberg MD, Tillotson GS, McDonald C. Clostridium difficile infections among hospitalized children, United States 1997-2006. Emerg Infect Dis 16:604-9.
95. Toltzis P, Kim J, Dul M, Zoltanski J, Smathers S, Zaoutis T. Presence of the epidemic North American Pulsed Field type 1 Clostridium difficile strain in hospitalized children. J Pediatr 2009; 154:607-8.
96. Lawley TD, Clare S, Walker AW, Goulding D, Stabler RA, Croucher N, et al. Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission and severe disease in immunocompromised hosts. Infect Immun 2009; 77:3661-9.
97. Jiang ZD, DuPont HL, Garey K, Price M, Graham G, Okhuysen P, et al. A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am J Gastroenterol 2006; 101:1112-6.
98. Lee JY, Kim H, Cha MY, Park HG, Kim YJ, Kim IY, et al. Clostridium difficile toxin A promotes dendritic cell maturation and chemokine CXCL2 expression through p38, IKK and the NFkappaB signaling pathway. J Mol Med 2009; 87:169-80.
99. Kim JM, Lee JY, Yoon YM, Oh YK, Youn J, Kim YJ. NFkappaB activation pathway is essential for the chemokine expression in intestinal epithelial cells stimulated with Clostridium difficile toxin A. Scand J Immunol 2006; 63:453-60.
100. He D, Sougioultzis S, Hagen S, Liu J, Keates S, Keates AC, et al. Clostridium difficile toxin A triggers human colonocyte IL-8 release via mitochondrial oxygen radical generation. Gastroenterology 2002; 122:1048-57.
101. Savidge TC, Pan WH, Newman P, O'Brien M, Anton PM, Pothoulakis C. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 2003; 125:413-20.
102. Castagliuolo I, Keates AC, Wang CC, Pasha A, Valenick L-, Kelly CP, et al. Clostridium difficile toxin A stimulates macrophage-inflammatory protein-2 production in rat intestinal epithelial cells. J Immunol 1998; 160:6039-45.
103. Kelly CP, Becker S, Linevsky JK, Joshi MA, O'Keane JC, Dickey BF, et al. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest 1994; 93:1257-65.
104. Chae S, Eckmann L, Miyamoto Y, Pothoulakis C, Karin M, Kagnoff MF. Epithelial cell IkappaB-kinase beta has an important protective role in Clostridium difficile toxin A-induced mucosal injury. J Immunol 2006; 177:1214-20.
105. Arzese A, Skerlavaj B, Tomasinsig L, Gennaro R, Zanetti M. Antimicrobial activity of SMAP-29 against the Bacteroides ffagilis group and clostridia. J Antimicrob Chemother 2003; 52:375-81.
106. Giesemann T, Guttenberg G, Aktories K. Human alpha-defensins inhibit Clostridium difficile toxin B. Gastroenterology 2008; 134:2049-58.
107. Giannasca PJ, Warny M. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 2004; 22:848-56.
108. Sanchez-Hurtado K, Corretge M, Mutlu E, McIlhagger R, Starr JM, Poxton IR. Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls. J Med Microbiol 2008; 57:717-24.
109. Songer JG. The emergence of Clostridium difficile as a pathogen of food animals. Anim Health Res Rev 2004; 5:321-6.
110. Songer JG, Anderson MA. Clostridium difficile: an important pathogen of food animals. Anaerobe 2006; 12:1-4.
111. Songer JG, Uzal FA. Clostridial enteric infections in pigs. J Vet Diagn Invest 2005; 17:528-36.
112. Waters EH, Orr JP, Clark EG, Schaufele CM. Typhlocolitis caused by Clostridium difficile in suckling piglets. J Vet Diagn Invest 1998; 10:104-8.
113. Indra A, Lassnig H, Baliko N, Much P, Fiedler A, Huhulescu S, et al. Clostridium difficile: a new zoonotic agent? Wien Klin Wochenschr 2009; 121:91-5.
114. Weese JS, Avery B P, Rousseau J, Reid-Smith RJ. Detection and enumeration of Clostridium difficile spores in retail beef and pork. Appl Environ Microbiol 2009; 75:5009-11.
115. Songer JG, Trinh HT, Killgore GE, Thompson AD, McDonald LC, Limbago BM. Clostridium difficile in retail meat products, USA 2007. Emerg Infect Dis 2009; 15:819-21.
116. Simango C, Mwakurudza S. Clostridium difficile in broiler chickens sold at market places in Zimbabwe and their antimicrobial susceptibility. Int J Food Microbiol 2008; 124:268-70.
117. Bakri MM, Brown DJ, Butcher J P, Sutherland AD. Clostridium difficile in ready-to-eat salads, Scotland. Emerg Infect Dis 2009; 15:817-8.
118. Al Saif N, Brazier JS. The distribution of Clostridium difficile in the environment of South Wales. J Med Microbiol 1996; 45:133-7.
119. Jhung MA, Thompson AD, Killgore GE, Zukowski WE, Songer G, Warny M, et al. Toxinotype V Clostridium difficile in humans and food animals. Emerg Infect Dis 2008; 14:1039-45.
120. Stoddart B, Wilcox MH. Clostridium difficile. Curr Opin Infect Dis 2002; 15:513-8.
121. Wilson KH, Silva J, Fekety FR. Suppression of Clostridium difficile by normal hamster cecal flora and prevention of antibiotic-associated cecitis. Infect Immun 1981; 34:626-8.
122. van Nood E, Speelman P, Kuijper EJ, Keller JJ. Struggling with recurrent Clostridium difficile infections: is donor faeces the solution? Euro Surveill 2009; 14.
123. Rolfe RD, Helebian S, Finegold SM. Bacterial interference between Clostridium difficile and normal fecal flora. J Infect Dis 1981; 143:470-5.
124. Yamamoto-Osaki T, Kamiya S, Sawamura S, Kai M, Ozawa A. Growth inhibition of Clostridium difficile by intestinal flora of infant faeces in continuous flow culture. J Med Microbiol 1994; 40:179-87.
125. Sambol S P, Merrigan MM, Tang JK, Johnson S, Gerding DN. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 2002; 186:1781-9.
126. Rolfe RD. Role of volatile fatty acids in colonization resistance to Clostridium difficile. Infect Immun 1984; 45:185-91.
127. Sorg JA, Sonenshein AL. Chenodeoxycholate is an inhibitor of Clostridium difficile spore germination. J Bacteriol 2009; 191:1115-7.
128. Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 2008; 190:2505-12.
129. Rakoff-Nahoum S, Medzhitov R. Gut-Associated Lymphoid Tissues. Berlin: Springer, 2006.
130. Bauer M P, van Dissel J T, Kuijper EJ. Clostridium difficile: controversies and approaches to management. Curr Opin Infect Dis 2009; 22:517-24.
131. Johnson S, Schriever C, Patel U, Patel T, Hecht DW, Gerding DN. Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009; 15:290-1.
132. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46:32-42.
133. Stepan C, Surawicz CM. Treatment strategies for recurrent and refractory Clostridium difficile-associated diarrhea. Expert Rev Gastroenterol Hepatol 2007; 1:295-305.
134. Johnson S, Schriever C, Galang M, Kelly C P, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44:846-8.
135. McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ. Intravenous immunoglobulin for the treatment of severe, refractory and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006; 49:640-5.
136. Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005; 128:764-70.
137. MacConnachie AA, Fox R, Kennedy DR, Seaton RA. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM 2009; 102:781-4.
138. Nieuwdorp M, van Nood E, Speelman P, van Heukelem HA, Jansen JM, Visser CE, et al. [Treatment of recurrent Clostridium difficile-associated diarrhoea with a suspension of donor faeces]. Ned Tijdschr Geneeskd 2008; 152:1927-32.
139. Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009; 15:285-9.
140. Merrigan MM, Sambol S P, Johnson S, Gerding DN. New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents 2009; 33:46-50.
141. Seal D, Borriello S P, Barclay F, Welch A, Piper M, Bonnycastle M. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol 1987; 6:51-3.
142. Zilberberg MD, Shorr A F, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States 2000-2005. Emerg Infect Dis 2008; 14:929-31.
143. Jagai J, Naumova E. Clostridium difficile-associated disease in the elderly, United States. Emerg Infect Dis 2009; 15:343-4.
144. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States 1999-2004. Emerg Infect Dis 2007; 13:1417-9.
145. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005; 173:1037-42.
146. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. Jama 2005; 294:2989-95.